Supreme Court Keeps Mifepristone Mail Access in Place, Preserving Telehealth Options for Physicians

Supreme Court Issues Temporary Ruling on Mail Access Pregnancy Termination Medication

On Thursday, the U.S. Supreme Court temporarily blocked a lower court ruling that would have restricted mail distribution of mifepristone, allowing current FDA rules for telehealth prescribing and pharmacy dispensing to remain in effect while litigation continues.

The case centers on a challenge to FDA policies that expanded remote access to the medication abortion drug during and after the pandemic. Had the lower court ruling taken effect, physicians nationwide could have faced renewed in-person dispensing requirements.

For Arizona physicians, the decision maintains continuity for telemedicine-based reproductive healthcare, particularly in rural and underserved areas where access to in-person services may be limited. The ruling also carries broader implications for FDA authority over nationally approved medications and future pharmaceutical regulation.

The Supreme Court’s order is temporary, and the underlying case is expected to continue through the federal courts in the coming months.